Prevalence of Intracranial Hemorrhage after Blunt Head Trauma in Patients on Pre-injury Dabigatran

Study Objective: Dabigatran etexilate was the first direct-acting oral anticoagulant approved in the United States. The rate of intracranial hemorrhage after blunt head trauma in patients on dabigatran is currently unknown, complicating adequate ability to accurately compare the risks and benefits of dabigatran to alternative anticoagulants. We aim to determine the prevalence of intracranial hemorrhage for patients on dabigatran presenting to a level 1 trauma center. Methods: This is a retrospective observational study of adult patients on dabigatran who presented to a Level 1 trauma center and received cranial computed tomography (CT) following blunt head trauma. Patients who met inclusion criteria underwent manual chart abstraction. Our primary outcome was intracranial hemorrhage on initial cranial CT. Results: A total of 33 eligible patient visits were included for analysis. Mean age was 74.8 years (SD 11.2, range 55-91). The most common cause of injury was ground level fall (n = 22, 66.7%). One patient (3.0%, 95% CI 0.1-15.8%) had intracranial hemorrhage on cranial CT. No patients (0%, 95% CI 0-8.7%) required neurosurgical intervention. One in-hospital death occurred. Results: A total of 33 eligible patient visits were included for analysis. Mean age was 74.8 years (SD 11.2, range 55-91). The most common cause of injury was ground level fall (n = 22, 66.7%). One patient (3.0%, 95% CI 0.1-15.8%) had intracranial hemorrhage on cranial CT. No patients (0%, 95% CI 0-8.7%) required neurosurgical intervention. One in-hospital death occurred. Conclusion: To our knowledge, this is the first study to evaluate the rate of intracranial hemorrhage after blunt head trauma for patients on dabigatran presenting to the emergency department. The intracranial hemorrhage rate in our study is similar to previous reports for patients on warfarin. Further studies are needed to determine if the rate of intracranial hemorrhage seen in our patient population is true for a larger patient population in more diverse clinical settings.